Metformin Reduces the Progression of Atherogenesis by Regulating the Sestrin2-mTOR Pathway in Obese and Diabetic Rats

Objective In previous research, we found that Sestrin2 has a strong association with plasma atherogenicity and combats the progression of atherogenesis by regulating the AMPK-mTOR pathway. Metformin, an activator of AMPK, is widely used as a first-line therapy for diabetes, but its role in preventi...

Полное описание

Библиографические подробности

Главные авторы:	Saravanakumar Sundararajan, Isaivani Jayachandran, Gautam Kumar Pandey, Saravanakumar Venkatesan, Anusha Rajagopal, Kuppan Gokulakrishnan, Muthuswamy Balasubramanyam, Viswanathan Mohan, Nagaraj Manickam
Формат:	Artigo
Язык:	Inglês
Опубликовано:	The Korean Society of Lipid and Atherosclerosis 2023-09-01
Серии:	Journal of Lipid and Atherosclerosis
Предметы:	metformin diabetes mellitus obesity atherosclerosis sestrin2
Online-ссылка:	https://www.e-jla.org/search.php?where=aview&id=10.12997/jla.2023.12.3.290&code=9992JLA&vmode=FULL
Метки:	Добавить метку Нет меток, Требуется 1-ая метка записи!